Scientists at the Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) in Thiruvananthapuram have identified a previously unknown mechanism through which malaria parasites survive exposure to artemisinin, the world's most widely used anti-malarial drug. The findings, published on 17 June as an Editor's Choice article in The Journal of Infectious Diseases, could reshape how researchers understand — and ultimately counter — drug resistance in malaria.

The Key Discovery

The study, led by Christeen Davis and colleagues at BRIC-RGCB, reveals that young red blood cells — called reticulocytes — create a protective cellular environment that allows malaria parasites to withstand drug-induced stress. Crucially, this mechanism operates independently of genetic mutations within the parasite itself, which had previously been considered the primary driver of artemisinin resistance.

'The biology of the host cell can significantly influence how malaria parasites respond to treatment. The parasite is not acting alone; it exploits the natural antioxidant defences present in young blood cells to protect itself from drug-induced stress,' said Dr Rajesh Chandramohanadas, senior author of the study and Principal Investigator at RGCB.

Why This Challenges Existing Understanding

For years, the scientific consensus held that artemisinin resistance was driven almost entirely by genetic changes within the Plasmodium parasite. This study challenges that assumption by demonstrating that the condition of the host cell — not just the parasite's own genetics — can determine whether treatment succeeds or fails.

Notably, this could explain a longstanding clinical puzzle: why some malaria patients experience delayed parasite clearance or persistent infection even when standard treatment is administered and no known genetic resistance markers are present.

Who Is Most at Risk

The implications are particularly significant for vulnerable groups. Children, anaemic patients, and individuals recovering from blood loss or other infections tend to have elevated reticulocyte levels — meaning their bodies may inadvertently provide malaria parasites with a more hospitable environment to survive drug treatment. This finding adds an important layer of clinical context to treatment planning for these populations.

Collaborators and Institutional Backing

The research was conducted by scientists from BRIC-RGCB — an institution under the Biotechnology Research and Innovation Council (BRIC) — in collaboration with researchers from IISER Thiruvananthapuram, Cosmopolitan Hospital, Thiruvananthapuram, and CSIR-National Chemical Laboratory (NCL), Pune.

Dr Beena Pillai, Director of BRIC-RGCB, said the discovery underscores the importance of studying host-parasite interactions when designing malaria treatment strategies.

What Comes Next

The research team believes future therapies could target not only the parasite but also the cellular environment that enables its survival — a dual-front approach that could significantly improve the efficacy of existing anti-malarial drugs. With malaria continuing to affect hundreds of millions of people globally each year, this host-cell-focused perspective opens a new avenue for tackling one of the world's most persistent infectious diseases.